BioNexus Gene Lab Corp Common stock (BGLC) - Total Liabilities
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has total liabilities worth $804.97K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioNexus Gene Lab Corp Common stock - Total Liabilities Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's total liabilities have evolved over time, based on quarterly financial data. See BGLC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
BioNexus Gene Lab Corp Common stock Competitors by Total Liabilities
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
One SA
WAR:FMG
|
Poland | zł47.35 Million |
|
Elecster Oyj A
HE:ELEAV
|
Finland | €17.36 Million |
|
BTU Metals Corp
V:BTU
|
Canada | CA$20.11K |
|
OFAL
NASDAQ:OFAL
|
USA | $4.44 Million |
|
Eko Export SA
WAR:EEX
|
Poland | zł44.67 Million |
|
Erika Carmel-Tech Ltd
TA:ERKA
|
Israel | ILA19.37 Million |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
Turkey | TL13.74 Million |
|
CDT Environmental Technology Investment Holdings Limited ordinary shares
NASDAQ:CDTG
|
USA | $8.34 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down BioNexus Gene Lab Corp Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BGLC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNexus Gene Lab Corp Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual total liabilities of BioNexus Gene Lab Corp Common stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.11 Million | +21.19% |
| 2023-12-31 | $1.74 Million | -16.06% |
| 2022-12-31 | $2.08 Million | -13.34% |
| 2021-12-31 | $2.39 Million | -30.65% |
| 2020-12-31 | $3.45 Million | +3071.74% |
| 2019-12-31 | $108.87K | -16.45% |
| 2018-12-31 | $130.31K | -88.94% |
| 2017-12-31 | $1.18 Million | +88026.70% |
| 2016-12-31 | $1.34K | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more